AZ/Daiichi Sankyo’s Enhertu picks up third breakthrough designation
The drug is being developed for metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have an HER2 mutation and with disease progression on or after platinum-based therapy
Read More
